Back to Treatments

Treatment

4-month Rifapentine-Moxifloxacin-Isoniazid-Pyrazinamide (RPT-M-H-Z) Regimen

1
Conditions
50
Trials
20K
Participants
55%
Average Safety

Condition Evidence

HIV/AIDS - Drug-susceptible Tuberculosis

50 trials · 20K participants

88% effectiveness · 55% safety
4-month Rifapentine-Moxifloxacin-Isoniazid-Pyrazinamide (RPT-M-H-Z) Regimen | DFDA